Phibro Animal Health Q4 sales beat estimates

Overview

• Phibro fiscal Q4 net sales rise 39%, beating analyst expectations, per LSEG data

• Adjusted EPS for fiscal Q4 beats estimates, while adjusted EBITDA misses, per LSEG data

• Growth driven by Zoetis MFA portfolio and higher international demand

Outlook

• Phibro expects FY 2026 net sales of $1.43 bln to $1.48 bln

• Company projects FY 2026 adjusted EBITDA of $225 mln to $235 mln

• Phibro anticipates FY 2026 net income of $73 mln to $83 mln

• Company sees FY 2026 diluted EPS of $1.79 to $2.03

Result Drivers

• ZOETIS ACQUISITION - Incremental revenues from Zoetis MFA portfolio drove a 77% increase in MFA and Other product sales

• INTERNATIONAL DEMAND - Higher international demand boosted sales of MFAs and vaccines, particularly in Latin America

• SG&A INVESTMENTS - Increased SG&A expenses due to strategic investments and higher employee-related costs

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Phibro Animal Health Corp is $24.00, about 36% below its August 26 closing price of $32.64

Press Release: ID:nBw78T1Tma